ERBB2 and breast carcinoma: An anti-HER2 ADC constructed using an EVCit–PABC linker showed superior long-term stability in vivo and an improved therapeutic effect in xenograft mouse models of HER2-positive breast cancer compared to a Val–Cit-containing comparator [59].